Gwynn Ison

2.2k total citations
16 papers, 439 citations indexed

About

Gwynn Ison is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Gwynn Ison has authored 16 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Economics and Econometrics and 7 papers in Cancer Research. Recurrent topics in Gwynn Ison's work include Cancer Genomics and Diagnostics (6 papers), Ethics in Clinical Research (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Gwynn Ison is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Ethics in Clinical Research (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Gwynn Ison collaborates with scholars based in United States, Mexico and Canada. Gwynn Ison's co-authors include Richard Pazdur, Julia A. Beaver, Caroline Schenkel, Thomas S. Uldrick, Suanna S. Bruinooge, Shenghui Tang, Geoffrey Kim, Barry A. Miller, Kieron Dunleavy and Michelle A. Rudek and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Gwynn Ison

15 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gwynn Ison United States 9 216 102 90 88 71 16 439
Navdeep Pal United States 11 189 0.9× 90 0.9× 127 1.4× 63 0.7× 55 0.8× 26 689
Jonathon Vallejo United States 12 309 1.4× 72 0.7× 152 1.7× 55 0.6× 68 1.0× 31 530
Joseph C. Del Paggio Canada 13 248 1.1× 109 1.1× 126 1.4× 384 4.4× 102 1.4× 28 796
Hedwig M. Blommestein Netherlands 16 296 1.4× 64 0.6× 113 1.3× 142 1.6× 25 0.4× 62 665
DA Berry United States 5 208 1.0× 303 3.0× 99 1.1× 92 1.0× 215 3.0× 7 643
Thomas Gwise United States 10 96 0.4× 56 0.5× 37 0.4× 56 0.6× 100 1.4× 24 316
Pierre Squifflet Belgium 12 214 1.0× 95 0.9× 86 1.0× 27 0.3× 42 0.6× 20 406
Ellen V. Sigal United States 10 103 0.5× 100 1.0× 57 0.6× 137 1.6× 54 0.8× 23 405
Laura L. Fernandes United States 10 369 1.7× 58 0.6× 149 1.7× 37 0.4× 24 0.3× 39 632
A.L. Vataire France 13 157 0.7× 158 1.5× 170 1.9× 114 1.3× 33 0.5× 34 478

Countries citing papers authored by Gwynn Ison

Since Specialization
Citations

This map shows the geographic impact of Gwynn Ison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gwynn Ison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gwynn Ison more than expected).

Fields of papers citing papers by Gwynn Ison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gwynn Ison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gwynn Ison. The network helps show where Gwynn Ison may publish in the future.

Co-authorship network of co-authors of Gwynn Ison

This figure shows the co-authorship network connecting the top 25 collaborators of Gwynn Ison. A scholar is included among the top collaborators of Gwynn Ison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gwynn Ison. Gwynn Ison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Shah, Mirat, Ting-Yu Chen, Gwynn Ison, et al.. (2025). Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Journal of Clinical Oncology. 43(19). 2218–2227. 1 indexed citations
2.
Lerro, Catherine C., Oladimeji Akinboro, Asma Dilawari, et al.. (2024). Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.. Journal of Clinical Oncology. 42(16_suppl). e23029–e23029.
3.
Liu, Wei, Mallorie H. Fiero, Bindu Kanapuru, et al.. (2023). Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration.. Journal of Clinical Oncology. 41(16_suppl). e18527–e18527. 1 indexed citations
4.
Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations
5.
Harvey, R. Donald, Suanna S. Bruinooge, Li Chen, et al.. (2021). Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations. Clinical Cancer Research. 27(9). 2430–2434. 29 indexed citations
6.
7.
Rahman, Nam Atiqur, Gwynn Ison, & Julia A. Beaver. (2020). Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions. Clinical Pharmacology & Therapeutics. 108(3). 419–421. 3 indexed citations
8.
Harvey, R. Donald, Wendy S. Rubinstein, Gwynn Ison, et al.. (2019). Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. Journal of Clinical Oncology. 37(18_suppl). LBA108–LBA108. 7 indexed citations
9.
Ison, Gwynn, V. Ellen Maher, Chana Weinstock, et al.. (2019). Causes of patient ineligibility in clinical trials of metastatic urothelial cancer.. Journal of Clinical Oncology. 37(15_suppl). 4556–4556. 1 indexed citations
10.
Bonomi, Philip, Gideon M. Blumenthal, Andrea Stern Ferris, et al.. (2018). Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology. 13(6). 748–751. 10 indexed citations
11.
Herzog, Thomas J., Gwynn Ison, Ronald D. Alvarez, et al.. (2017). FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology. 147(1). 3–10. 29 indexed citations
12.
Beaver, Julia A., Gwynn Ison, & Richard Pazdur. (2017). Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials. New England Journal of Medicine. 376(16). 1504–1505. 61 indexed citations
13.
Uldrick, Thomas S., Gwynn Ison, Michelle A. Rudek, et al.. (2017). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group. Journal of Clinical Oncology. 35(33). 3774–3780. 102 indexed citations
14.
Kim, Edward S., Jennifer Atlas, Gwynn Ison, & Jennifer L. Ersek. (2016). Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application. American Society of Clinical Oncology Educational Book. 35(36). 83–90. 16 indexed citations
15.
Kim, Edward S., Jennifer Atlas, Gwynn Ison, & Jennifer L. Ersek. (2016). Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application. American Society of Clinical Oncology Educational Book. 36. 83–90. 4 indexed citations
16.
Ricks, Tiffany K., Haw-Jyh Chiu, Gwynn Ison, et al.. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. Frontiers in Oncology. 5. 222–222. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Navdeep Pal Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by Joseph C. Del Paggio Breakdown of academic impact, for papers by Hedwig M. Blommestein Breakdown of academic impact, for papers by DA Berry Breakdown of academic impact, for papers by Thomas Gwise Breakdown of academic impact, for papers by Pierre Squifflet Breakdown of academic impact, for papers by Ellen V. Sigal Breakdown of academic impact, for papers by Laura L. Fernandes Breakdown of academic impact, for papers by A.L. Vataire
Rankless by CCL
2026